Evidence map›Paper›PMID 29263421›Full record

ReviewProstate cancer and prostatic diseases2018

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

Megan McNamara, Christopher Sweeney, Emmanuel S Antonarakis, Andrew J Armstrong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Megan McNamaraDuke University Medical Center and Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, NC, 27710, USA. megan.diehl@duke.edu.
Christopher SweeneyDana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Emmanuel S AntonarakisJohns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, 212873, USA.
Andrew J ArmstrongDuke University Medical Center and Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0001-7012-1754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUntil 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space.

methodsWe conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC.

resultsWe describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC.

conclusionsThe management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.

Indexed as

Androgen AntagonistsAndrostenesAntineoplastic AgentsClinical Trials, Phase III as TopicDisease-Free SurvivalDocetaxelEvidence-Based MedicineHumansMaleProstatic NeoplasmsRandomized Controlled Trials as TopicSurvival AnalysisTreatment OutcomeabirateroneAndrogen AntagonistsAndrostenesAntineoplastic AgentsDocetaxel

Identifiers

PMID29263421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.